Key Points
- Broadwood Partners bought 521,739 Oncocyte shares on Feb. 10 at $5.75 each (~$3.0M), increasing its stake to 11,931,839 shares (a 4.57% rise) worth about $68.6M.
- Oncocyte opened around $5.58 with a market cap near $159.9M, reported quarterly EPS of -$0.34 and revenue of $0.26M, and shows extremely negative profitability (ROE -983.3%, net margin -1,380.7%).
- Analyst sentiment is negative on balance — MarketBeat's average rating is "Sell", with Weiss Ratings at "sell (d-)" while Wall Street Zen assigns a "Hold".
Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 521,739 shares of Oncocyte stock in a transaction dated Tuesday, February 10th. The stock was purchased at an average price of $5.75 per share, with a total value of $2,999,999.25. Following the completion of the purchase, the insider owned 11,931,839 shares of the company's stock, valued at approximately $68,608,074.25. The trade was a 4.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Oncocyte Trading Down 2.6%
Shares of NASDAQ IMDX opened at $5.58 on Friday. Oncocyte Corp has a 52 week low of $2.21 and a 52 week high of $8.51. The firm has a 50 day moving average price of $6.38. The stock has a market capitalization of $159.92 million, a price-to-earnings ratio of -1.97 and a beta of 1.35.
Oncocyte (NASDAQ:IMDX - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.34) earnings per share (EPS) for the quarter. Oncocyte had a negative return on equity of 983.30% and a negative net margin of 1,380.69%.The business had revenue of $0.26 million for the quarter.
Analysts Set New Price Targets
Several research firms have commented on IMDX. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oncocyte in a report on Monday, December 29th. Wall Street Zen raised Oncocyte to a "hold" rating in a report on Saturday, November 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Oncocyte has an average rating of "Sell".
Read Our Latest Research Report on Oncocyte
Oncocyte Company Profile
(
Get Free Report)
Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.
Oncocyte's product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
